KR20130026418A - Ｈｅｒ2 의 세포외 도메인 2 및 3 에 대한 항체 - Google Patents

Ｈｅｒ2 의 세포외 도메인 2 및 3 에 대한 항체 Download PDF

Info

Publication number
KR20130026418A
KR20130026418A KR1020127017264A KR20127017264A KR20130026418A KR 20130026418 A KR20130026418 A KR 20130026418A KR 1020127017264 A KR1020127017264 A KR 1020127017264A KR 20127017264 A KR20127017264 A KR 20127017264A KR 20130026418 A KR20130026418 A KR 20130026418A
Authority
KR
South Korea
Prior art keywords
cancer
affinity ligand
her2
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127017264A
Other languages
English (en)
Korean (ko)
Inventor
마티아스 울렌
요한 록베르그
Original Assignee
아트라스 테라퓨틱스 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아트라스 테라퓨틱스 에이비 filed Critical 아트라스 테라퓨틱스 에이비
Publication of KR20130026418A publication Critical patent/KR20130026418A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020127017264A 2008-06-13 2008-12-12 Ｈｅｒ2 의 세포외 도메인 2 및 3 에 대한 항체 Withdrawn KR20130026418A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2008155676A JP2010006705A (ja) 2008-06-13 2008-06-13 Ｈｅｒ２サブセット
JPJP-P-2008-155676 2008-06-13
US7635208P 2008-06-27 2008-06-27
US61/076,352 2008-06-27
PCT/SE2008/000694 WO2009151356A1 (en) 2008-06-13 2008-12-12 Antibodies against extracellular domains 2 and 3 or her2

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020107027939A Division KR20110036534A (ko) 2008-06-13 2008-12-12 Ｈｅｒ2 의 세포외 도메인 2 및 3 에 대한 항체

Publications (1)

Publication Number Publication Date
KR20130026418A true KR20130026418A (ko) 2013-03-13

Family

ID=40427661

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127017264A Withdrawn KR20130026418A (ko) 2008-06-13 2008-12-12 Ｈｅｒ2 의 세포외 도메인 2 및 3 에 대한 항체
KR1020107027939A Ceased KR20110036534A (ko) 2008-06-13 2008-12-12 Ｈｅｒ2 의 세포외 도메인 2 및 3 에 대한 항체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020107027939A Ceased KR20110036534A (ko) 2008-06-13 2008-12-12 Ｈｅｒ2 의 세포외 도메인 2 및 3 에 대한 항체

Country Status (8)

Country Link
US (1) US20110158988A1 (enExample)
EP (1) EP2294088A1 (enExample)
JP (1) JP2010006705A (enExample)
KR (2) KR20130026418A (enExample)
CN (1) CN102099376A (enExample)
AU (1) AU2008357729A1 (enExample)
CA (1) CA2727941A1 (enExample)
WO (1) WO2009151356A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101759209B1 (ko) 2010-01-22 2017-07-19 성균관대학교산학협력단 Ｈｅｒ－２ 과발현 유방암 세포 또는 조직에 특이적으로 결합할 수 있는 핵산 압타머 및 그 용도
US8609095B2 (en) 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
CA3051311A1 (en) * 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2
AU2016201799B2 (en) * 2010-05-27 2017-09-07 Genmab A/S Monoclonal antibodies aganst HER2 epitope
NZ604007A (en) * 2010-05-27 2015-03-27 Genmab As Monoclonal antibodies against her2 epitope
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
CN105017425B (zh) * 2014-04-30 2018-02-16 京天成生物技术(北京)有限公司 抗her2中和活性单克隆抗体及其应用
CN110121505B (zh) 2016-12-28 2023-08-01 株式会社绿十字细胞治疗 嵌合抗原受体和表达其的自然杀伤细胞
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
EP3712178A4 (en) 2017-11-14 2021-08-11 Green Cross Lab Cell Corporation ANTI-HER2 ANTIBODIES OR ANTIGIBODY FRAGMENT THEREOF AND CHIMERAIR ANTIGEN RECEPTOR WITH IT
WO2019116089A2 (en) * 2017-12-11 2019-06-20 Medizinische Universitaet Wien A method of producing a vaccine composition and uses thereof
EP3837035B1 (en) 2018-08-16 2026-05-20 Emd Millipore Corp Closed bioprocessing device
US20210238305A1 (en) * 2019-03-01 2021-08-05 Remegen Co., Ltd. Antibody for her2 concomitant diagnosis immunohistochemical detection and application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US6514942B1 (en) * 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
US5783404A (en) * 1995-04-13 1998-07-21 Amgen Inc. Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
AU2087401A (en) * 1999-12-10 2001-06-18 Epimmune, Inc. Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
CA2450793A1 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
CN1136917C (zh) * 2001-10-10 2004-02-04 北京迪威华宇生物技术有限公司 一种卡介苗热休克蛋白65和多表位her-2抗原融合蛋白重组蛋白疫苗
WO2004052917A2 (en) * 2002-12-10 2004-06-24 Epimmune Inc. Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
HRP20141111T1 (hr) * 2004-07-22 2015-01-02 Genentech, Inc. Sastav her2-protutijela
ATE473758T1 (de) * 2006-04-13 2010-07-15 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh Her-2/neu multipeptidimpfstoff
NZ574093A (en) * 2006-06-12 2011-03-31 Symphogen As Pan-cell surface receptor- specific therapeutics
CN101165068B (zh) * 2006-10-18 2011-09-21 上海复旦张江生物医药股份有限公司 抗HER2/ErbB2抗原的单克隆抗体及其制备方法和药物组合物

Also Published As

Publication number Publication date
US20110158988A1 (en) 2011-06-30
JP2010006705A (ja) 2010-01-14
AU2008357729A8 (en) 2011-02-03
WO2009151356A1 (en) 2009-12-17
CA2727941A1 (en) 2009-12-17
CN102099376A (zh) 2011-06-15
AU2008357729A1 (en) 2009-12-17
KR20110036534A (ko) 2011-04-07
EP2294088A1 (en) 2011-03-16

Similar Documents

Publication Publication Date Title
KR20110036534A (ko) Ｈｅｒ2 의 세포외 도메인 2 및 3 에 대한 항체
JP6823094B2 (ja) Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン
DK2494359T3 (en) PODXL protein in colorectal cancer
KR102167550B1 (ko) Dll3 결합 시약을 포함하는 암에 대한 치료적 및 진단적 타겟
JP2019500405A (ja) 癌の成長を抑制する結合分子
TW200804420A (en) Antibodies directed to HER-3 and uses thereof
KR20140107615A (ko) 엑소좀 검출용 모노클로날 항체
JP2022064969A (ja) 食道癌の検出および治療のための組成物および方法
JP2022009080A (ja) 卵巣癌の検出および治療のための組成物および方法
JP2021167831A (ja) 胃癌の検出および治療のための組成物および方法
US20250122303A1 (en) Treatment and prevention of cancer using her3 antigen-binding molecules
KR102350251B1 (ko) 새로운 igf-1r 항체 및 암의 진단을 위한 그의 용도
JP2023533857A (ja) 抗ｋｌｋ２抗体に対する抗イディオタイプ抗体
CN112823168A (zh) 结合her2的四聚体多肽
KR102350259B1 (ko) Igf-1r 항체 및 암의 진단을 위한 그의 용도
US11236178B2 (en) Methods of using monoclonal antibodies targeting epitopes of ASPH
JP2024530059A (ja) 個別化されたがん免疫療法を創出するためのプロセス
EP3145545B1 (en) Bak binding proteins
JP2017508781A (ja) 癌治療に使用するためのアドレノメデュリンバインダー
KR20210024007A (ko) 암이 있는 개체에서 항-lif 항체 치료에 대한 반응을 개선하기 위한 방법
HK40051469A (en) Her2-binding tetrameric polypeptides
JP2003310276A (ja) １２１４位チロシンがリン酸化したＫＤＲ／Ｆｌｋ−１に対する情報伝達分子の結合を阻害する物質およびその利用方法

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20120702

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid